CR10879A - Cyclized derivatives as eg-5 inhibitors - Google Patents

Cyclized derivatives as eg-5 inhibitors

Info

Publication number
CR10879A
CR10879A CR10879A CR10879A CR10879A CR 10879 A CR10879 A CR 10879A CR 10879 A CR10879 A CR 10879A CR 10879 A CR10879 A CR 10879A CR 10879 A CR10879 A CR 10879A
Authority
CR
Costa Rica
Prior art keywords
inhibitors
cyclized derivatives
cyclized
derivatives
Prior art date
Application number
CR10879A
Other languages
English (en)
Inventor
Rustum Boyce
Eric Martin
Weibo Wang
Hong Yang
Paul A Barsanti
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CR10879A publication Critical patent/CR10879A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CR10879A 2007-01-05 2009-06-19 Cyclized derivatives as eg-5 inhibitors CR10879A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88374007P 2007-01-05 2007-01-05

Publications (1)

Publication Number Publication Date
CR10879A true CR10879A (es) 2009-08-05

Family

ID=39577804

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10879A CR10879A (es) 2007-01-05 2009-06-19 Cyclized derivatives as eg-5 inhibitors

Country Status (30)

Country Link
US (3) US7820646B2 (es)
EP (1) EP2106399A2 (es)
JP (1) JP2010515687A (es)
KR (1) KR20090097210A (es)
CN (1) CN101622247A (es)
AR (1) AR064760A1 (es)
AU (1) AU2008205169B2 (es)
BR (1) BRPI0806264A2 (es)
CA (1) CA2674318A1 (es)
CL (1) CL2008000029A1 (es)
CO (1) CO6561828A2 (es)
CR (1) CR10879A (es)
DO (1) DOP2009000169A (es)
EA (1) EA200900924A1 (es)
EC (1) ECSP099485A (es)
GE (1) GEP20125415B (es)
GT (1) GT200900192A (es)
HN (1) HN2009001262A (es)
MA (1) MA31080B1 (es)
MX (1) MX2009007260A (es)
NI (1) NI200900134A (es)
NZ (1) NZ577727A (es)
PE (1) PE20081850A1 (es)
SM (1) SMP200900065B (es)
SV (1) SV2009003325A (es)
TN (1) TN2009000287A1 (es)
TW (1) TW200836722A (es)
UA (1) UA97821C2 (es)
WO (1) WO2008086122A2 (es)
ZA (1) ZA200904175B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252832B2 (en) 2007-12-14 2012-08-28 Novartis Ag Kinesin inhibitors as cancer therapeutics
EA201201404A1 (ru) 2010-04-15 2013-04-30 Новартис Аг Триазолы как ингибиторы кбв (кинезин-белок веретена)
WO2011128388A2 (en) * 2010-04-15 2011-10-20 Novartis Ag Oxazole and thiazole compounds as ksp inhibitors
EP2390247A1 (en) 2010-05-26 2011-11-30 Netherlands Organisation for Scientific Research (Advanced Chemical Technologies for Sustainability) Preparation of caprolactone, caprolactam, 2,5-tetrahydrofuran dimethanol, 1,6-hexanediol or 1,2,6-hexanetriol from 5-hydroxymethyl-2-furfuraldehyde
GB201113538D0 (en) 2011-08-04 2011-09-21 Karobio Ab Novel estrogen receptor ligands
EP2968591A1 (en) * 2013-03-15 2016-01-20 Novartis AG Cell proliferation inhibitors and conjugates thereof
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
CN106163568B (zh) * 2013-12-23 2021-03-23 拜耳制药股份公司 含纺锤体驱动蛋白（ksp）的抗体药物偶联物（adc）
EP3310440A1 (de) * 2015-06-22 2018-04-25 Bayer Pharma Aktiengesellschaft Binder-wirkstoff-konjugate (adcs) und binder-prodrug-konjugate (apdcs) mit enzymatisch spaltbaren gruppen
CN105367506B (zh) * 2015-12-08 2021-02-05 华润双鹤药业股份有限公司 手性高哌嗪环的制备方法
CN105330657B (zh) * 2015-12-08 2019-05-21 华润双鹤药业股份有限公司 5-氯-2-[5-(r)-甲基-1,4-二氮杂环庚烷-1-]苯并恶唑的制备方法
JP7022707B2 (ja) 2016-06-15 2022-02-18 バイエル・ファルマ・アクティエンゲゼルシャフト Ｋｓｐ阻害剤および抗ｃｄ１２３抗体を含む特異的抗体－薬物－コンジュゲート（ａｄｃ）
PE20191235A1 (es) 2016-12-21 2019-09-11 Bayer Pharma AG Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente
EP3558387B1 (de) 2016-12-21 2021-10-20 Bayer Pharma Aktiengesellschaft Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren
CA3103327A1 (en) 2018-06-18 2019-12-26 Bayer Aktiengesellschaft Binder/active agent conjugates directed against cxcr5, having enzymatically cleavable linkers and improved activity profile
CN119859151A (zh) * 2023-10-19 2025-04-22 北京振东光明药物研究院有限公司 从白土苓中分离得到的生物碱类化合物及其制备方法和应用

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2550959C3 (de) 1975-11-13 1980-12-04 Hoechst Ag, 6000 Frankfurt Tetrazolyl-imidazole und Tetrazolyl--benzimidazole, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
GB2157285B (en) 1984-04-11 1987-10-28 Erba Farmitalia 1h, 7h-pyrazolo1, 5-a pyrimidine-7-one derivatives and process for their preparation
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5859012A (en) * 1996-04-03 1999-01-12 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2001505585A (ja) 1996-12-16 2001-04-24 藤沢薬品工業株式会社 新規アミド化合物およびそれらの一酸化窒素シンターゼ阻害剤としての用途
US6117940A (en) 1997-10-17 2000-09-12 Mjalli; Adnan M. M. Amino-ketone solid support templates
US6172087B1 (en) 1998-06-03 2001-01-09 Gpi Nil Holding, Inc. N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses
US6271241B1 (en) 1999-04-02 2001-08-07 Neurogen Corporation Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
EP1165519A1 (en) 1999-04-02 2002-01-02 Neurogen Corporation Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics
TWI292316B (en) 1999-10-11 2008-01-11 Sod Conseils Rech Applic Pharmaceutical composition of thiazole derivatives intended to inhibit mao and/or lipidic peroxidation and/or to act as modulators of sodium channels and the use thereof
US7291641B2 (en) 1999-10-11 2007-11-06 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
US20040132788A1 (en) 1999-10-11 2004-07-08 Chabrier De Lassauniere Pierre-Etienne Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
BR0015110A (pt) 1999-10-27 2002-07-02 Cytokinetics Inc Métodos de tratamento de doenças de proliferação celular, de tratamento de um distúrbio associado com a atividade da cinesina ksp, de inibição da cinesina ksp, de triagem de moduladores da cinesina kps e de triagem de compostos que se ligam na cinesina ksp, e, compostos
WO2001083575A1 (en) 2000-05-02 2001-11-08 Advanced Syntech, Llc A Kentucky Limited Liability Corporation A novel solid support template for preparation of highly functionalized heterocycle compounds
WO2001094318A2 (en) 2000-06-05 2001-12-13 Ortho-Mcneil Pharmaceutical, Inc. Method for synthesis of substituted azole libraries
US6683191B2 (en) 2000-06-05 2004-01-27 Ortho-Mcneil Pharmaceuticals, Inc. Method for synthesis of substituted azole libraries
ES2282275T3 (es) 2000-08-01 2007-10-16 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivados de imidazolilo.
MXPA03003039A (es) 2000-10-06 2003-10-15 Neurogen Corp Derivados de indola y bencimidazola como moduladores del receptor crf.
AU2002221239A1 (en) 2000-12-07 2002-06-18 Astrazeneca Ab Therapeutic benzimidazole compounds
US6964967B2 (en) 2000-12-11 2005-11-15 Amgen, Inc. Substituted pyrido[2,3-d]pyrimidines and methods for their use
WO2002057244A1 (en) 2001-01-19 2002-07-25 Cytokinetics, Inc. Phenothiazine kinesin inhibitors
US20040132830A1 (en) 2001-01-19 2004-07-08 Finer Jeffrey T Triphenylmethane kinesin inhibitors
EP1444209A4 (en) 2001-11-07 2005-02-16 Merck & Co Inc INHIBITORS OF MITOTIC KINESINS
US6753428B2 (en) 2001-11-20 2004-06-22 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
WO2003049527A2 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
ATE372341T1 (de) 2001-12-06 2007-09-15 Merck & Co Inc Inhibitoren von mitotischem kinesin
JP4467979B2 (ja) 2001-12-06 2010-05-26 メルク・シャープ・エンド・ドーム・コーポレイション 有糸分裂キネシン阻害剤
JP2005515208A (ja) 2001-12-06 2005-05-26 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂性キネシン阻害剤
JP4391825B2 (ja) 2001-12-06 2009-12-24 メルク エンド カムパニー インコーポレーテッド 有糸分裂キネシン阻害剤
WO2003059289A2 (en) 2002-01-10 2003-07-24 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues
WO2003070701A2 (en) 2002-02-15 2003-08-28 Cytokinetics, Inc. Syntheses of quinazolinones
WO2003079973A2 (en) 2002-03-08 2003-10-02 Merck & Co., Inc. Mitotic kinesin inhibitors
US7026312B2 (en) 2002-03-14 2006-04-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
DE10211770A1 (de) 2002-03-14 2003-10-02 Boehringer Ingelheim Pharma Neue substituierte Piperidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
ATE471931T1 (de) 2002-04-17 2010-07-15 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren
GB0209995D0 (en) 2002-05-01 2002-06-12 Merck Sharp & Dohme Therapeutic agents
US7030144B2 (en) 2002-05-02 2006-04-18 Neurogen Corporation Substituted imidazole derivatives: GABAA receptor ligands
US6982268B2 (en) 2002-05-08 2006-01-03 Neurogen Corporation Substituted imidazolylmethyl pyridine and pyrazine derivatives GABAA receptor ligands
AU2003270015A1 (en) 2002-05-09 2003-12-02 Cytokinetics, Inc. Compounds, compositions, and methods
WO2003094839A2 (en) 2002-05-09 2003-11-20 Cytokinetics, Inc. Pyrimidinone compounds, compositions and methods
WO2004026226A2 (en) 2002-05-10 2004-04-01 Cytokinetics, Inc. Compounds, compositions and methods
AU2003237881A1 (en) 2002-05-17 2003-12-02 Neurogen Corporation Substituted ring-fused imidazole derivates: gabaa receptor ligands
JP2005536475A (ja) 2002-05-23 2005-12-02 サイトキネティクス・インコーポレーテッド 化合物、組成物、および方法
US20050234080A1 (en) * 2002-05-23 2005-10-20 Coleman Paul J Mitotic kinesin inhibitors
US7301028B2 (en) 2002-06-14 2007-11-27 Merck & Co., Inc. Mitotic kinesin inhibitors
EP1556357A4 (en) 2002-06-14 2006-09-13 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
KR20050010515A (ko) 2002-06-14 2005-01-27 머크 앤드 캄파니 인코포레이티드 유사분열 키네신 억제제
WO2004004652A2 (en) 2002-07-08 2004-01-15 Merck & Co., Inc. Mitotic kinesin binding site
WO2004006865A2 (en) 2002-07-17 2004-01-22 Cytokinetics, Inc. Compounds, compositions, and methods
EP1537089A4 (en) 2002-07-23 2008-04-16 Cytokinetics Inc CONNECTIONS, COMPOSITIONS AND PROCEDURES
AU2003262747A1 (en) 2002-08-21 2004-03-11 Cytokinetics, Inc. Compounds, compositions, and methods
JP2005539062A (ja) 2002-09-13 2005-12-22 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
CN100579579C (zh) 2002-10-01 2010-01-13 诺华疫苗和诊断公司 抗癌及抗感染性疾病组合物及其使用方法
ATE335732T1 (de) 2002-11-08 2006-09-15 Neurogen Corp 4-imidazol-1-ylmethylpyrimidinderivate als liganden für gabaa-rezeptoren
EP1581520A4 (en) * 2002-12-13 2006-08-23 Smithkline Beecham Corp COMPOUNDS, COMPOSITIONS AND METHODS
WO2004064741A2 (en) 2003-01-17 2004-08-05 Cytokinetics Inc. Compounds, compositions, and methods
WO2004071448A2 (en) 2003-02-12 2004-08-26 Transtech Pharma Inc. Substituted azole derivatives as inhibitors of protein tyrosine phosphatases
US20080021079A1 (en) 2003-05-07 2008-01-24 Han-Jie Zhou Compounds, Compositions, and Methods
JP2007500746A (ja) 2003-05-15 2007-01-18 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
WO2004113335A2 (en) 2003-06-20 2004-12-29 Chiron Corporation Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents
WO2005041888A2 (en) * 2003-11-03 2005-05-12 Cytokinetics, Inc. Pyrimidin-4-one compounds, compositions and methods
NZ548208A (en) 2004-02-12 2010-09-30 Transtech Pharma Inc Substituted azole derivatives, compositions, and methods of use
PT1732926E (pt) 2004-04-06 2009-04-03 Novartis Vaccines & Diagnostic Inibidores de cinesinas mitóticas
EP1740550A1 (en) 2004-04-14 2007-01-10 Pfizer Limited Sulphur-linked imidazole compounds for the treament of hiv
US7618981B2 (en) 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
CA2564215A1 (en) 2004-05-21 2005-12-01 Chiron Corporation Substituted quinoline derivatives as mitotic kinesin inhibitors
JP4836280B2 (ja) * 2004-06-18 2011-12-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 癌を治療するためのキネシンスピンドルタンパク質（ｋｓｐ）阻害剤としてのｎ−（１−（１−ベンジル−４−フェニル−１ｈ−イミダゾール−２−イル）−２，２−ジメチルプロピル）ベンズアミド誘導体および関連化合物
KR20070072598A (ko) 2004-10-19 2007-07-04 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 인돌 및 벤지미다졸 유도체
TW200800951A (en) 2005-08-09 2008-01-01 Novartis Ag Substituted imidazole compounds as KSP inhibitors
MX2009005071A (es) 2006-11-13 2009-05-25 Novartis Ag Compuestos de pirazol y triazol sustituidos como inhibidores de ksp.

Also Published As

Publication number Publication date
EA200900924A1 (ru) 2009-12-30
BRPI0806264A2 (pt) 2011-08-30
US7820646B2 (en) 2010-10-26
AU2008205169B2 (en) 2012-02-02
EP2106399A2 (en) 2009-10-07
JP2010515687A (ja) 2010-05-13
AR064760A1 (es) 2009-04-22
NI200900134A (es) 2010-07-05
CN101622247A (zh) 2010-01-06
SMP200900065B (it) 2010-09-10
US20110003791A1 (en) 2011-01-06
KR20090097210A (ko) 2009-09-15
WO2008086122A2 (en) 2008-07-17
CO6561828A2 (es) 2012-11-15
GEP20125415B (en) 2012-03-12
AU2008205169A1 (en) 2008-07-17
CA2674318A1 (en) 2008-07-17
PE20081850A1 (es) 2009-02-05
TW200836722A (en) 2008-09-16
MX2009007260A (es) 2009-07-10
SV2009003325A (es) 2011-08-09
US20120189623A1 (en) 2012-07-26
MA31080B1 (fr) 2010-01-04
SMAP200900065A (it) 2009-09-07
ZA200904175B (en) 2010-04-28
GT200900192A (es) 2010-06-24
CL2008000029A1 (es) 2008-04-04
ECSP099485A (es) 2009-08-28
TN2009000287A1 (en) 2010-12-31
US20080207589A1 (en) 2008-08-28
HN2009001262A (es) 2012-01-09
WO2008086122A3 (en) 2008-10-16
NZ577727A (en) 2012-03-30
DOP2009000169A (es) 2009-08-31
UA97821C2 (en) 2012-03-26

Similar Documents

Publication Publication Date Title
CR10879A (es) Cyclized derivatives as eg-5 inhibitors
DK2164844T3 (da) Pyrimidinyl-pyridazinonderivater
DK2209786T3 (da) Pyrimidinsubstituerede purinderivater
DK2308877T3 (da) Imidazopyridin-2-on-derivater
ATE549340T1 (de) Spiroindolinon-derivate als mdm2-p53 inhibitoren
BRPI0818457A2 (pt) Derivados de oxadiazol
EP2192838A4 (en) HETEROCYCLIC NEKROPTOSIS HEMMER
DOP2007000084A (es) Derivados de dihidropirazolopirimidinona
BRPI0820112A2 (pt) Derivados de isoxazol-piridina
BRPI0918846A2 (pt) inibidores de cinase heterocíclica
BRPI0809992A2 (pt) Derivados de pirrolopirimidina
BRPI0813836A2 (pt) Derivados pirazólicos
BRPI0820113A2 (pt) Derivados de isoxazolo-piridazina
EP2266989A4 (en) HETEROCYCLIC DERIVATIVES
ATE506358T1 (de) 2-benzylpyridazinonderivate als met-kinasehemmer
BRPI0817935A2 (pt) Derivados de biarila
BRPI0915064A2 (pt) derivados de qunoxalinadiona
ATE518837T1 (de) Indazolamidderivate
ATE533761T1 (de) Imidazolidinonderivate
BRPI0814236A2 (pt) Derivados de quinazolinamida
BRPI0913832A2 (pt) derivados de pirrolopiridinilpirimidin-2-ilamina
BRPI0820649A2 (pt) Derivados de isoxazalo-pirazina
DK2152370T3 (da) Aryletherpyridazinonderivater
DK2275414T3 (da) Cyclopentylacrylamidderivat
BRPI0720547A2 (pt) Inibidores de metaloprotease derivada de heterocíclico